Advertisement
Screener

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Overview

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -1.81; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -1.23; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -1.90; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -1.44; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$6.30$7.96$10.06$12.72$16.08$20.332025-09-292026-09-29$2.03$4.06$8.11$16.20$32.36$64.632021-09-292026-09-29$2.03$5.61$15.49$42.78$118.09$326.032016-09-292026-09-29$2.03$5.61$15.49$42.78$118.09$326.032014-10-272026-09-29$2.03$5.61$15.49$42.78$118.09$326.032014-10-272026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$6.63
Previous close
$6.92
Change
-$0.29
Change (%)
-4.19%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

CRBP
-18.55%
S&P 500
(m)

1 year

CRBP
-45.92%
S&P 500
(m)

3 years

CRBP
-1.63%
S&P 500
(m)

5 years

CRBP
-78.12%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -1.81

-1.98-1.75-1.52-1.28-1.0531 Mar 2025: estimate (m); actual -1.3931 Mar 2025(m)30 Jun 2025: estimate (m); actual -1.4430 Jun 2025(m)30 Sept 2025: estimate (m); actual -1.9030 Sept 2025(m)31 Mar 2026: estimate (m); actual -1.2331 Mar 2026(m)30 Jun 2026: estimate (m); actual -1.8130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-1.81(m)(m)
1 Jan 202631 Mar 2026(m)-1.23(m)(m)
1 Jul 202530 Sept 2025(m)-1.90(m)(m)
1 Apr 202530 Jun 2025(m)-1.44(m)(m)
1 Jan 202531 Mar 2025(m)-1.39(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -5.90

-11.23-9.30-7.37-5.43-3.5031 Dec 2021: estimate (m); actual -11.1531 Dec 2021(m)31 Dec 2022: estimate (m); actual -10.1531 Dec 2022(m)31 Dec 2023: estimate (m); actual -10.3131 Dec 2023(m)31 Dec 2024: estimate (m); actual -3.6831 Dec 2024(m)31 Dec 2025: estimate (m); actual -5.9031 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-5.90(m)(m)
1 Jan 202431 Dec 2024(m)-3.68(m)(m)
1 Jan 202331 Dec 2023(m)-10.31(m)(m)
1 Jan 202231 Dec 2022(m)-10.15(m)(m)
1 Jan 202131 Dec 2021(m)-11.15(m)(m)

Revenue vs. Earnings

USD

30 Sept 2022 ■ Revenue 0.00M ■ Earnings -8.78M — Profit margin (m)

-19.21M-12551.3%-12.07M-9112.5%-4.93M-5673.8%2.21M-2235.0%30 Jun 2021: revenue 0.14M; earnings -17.14M; profit margin -12550.25%30 Jun 202130 Sept 2021: revenue 0.10M; earnings -2.18M; profit margin -2236.01%30 Sept 202131 Mar 2022: revenue 0.00M; earnings -9.44M; profit margin (m)31 Mar 202230 Sept 2022: revenue 0.00M; earnings -8.78M; profit margin (m)30 Sept 2022

31 Dec 2022 ■ Revenue 0.00M ■ Earnings -42.35M — Profit margin (m)

-128.96M-5177.4%-68.03M-3517.2%-7.10M-1856.9%53.83M-196.7%31 Dec 2019: revenue 36.14M; earnings -71.45M; profit margin -197.69%31 Dec 201931 Dec 2020: revenue 3.94M; earnings -111.27M; profit margin -2826.08%31 Dec 202031 Dec 2021: revenue 0.88M; earnings -45.64M; profit margin -5176.38%31 Dec 202131 Dec 2022: revenue 0.00M; earnings -42.35M; profit margin (m)31 Dec 2022

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$6.63(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$6.63High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning CRBP

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending 31 Dec 2022.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-42.35M
Profit margin
(m)
Return on assets · 12 month
-48.66%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
141.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.38M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-15.81%*
Total return · month
-39.23%*
Total return · quarter
-26.17%*
Total return · half year
-23.88%*
Total return · year to date
-18.55%*
Total return · 1 year
-45.92%*
Total return · 3 years
-1.63%*
Total return · 5 years
-78.12%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$0.00
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
56.93%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Corbus Pharmaceuticals Holdings, Inc. Overview

View more →

(m)

(m)

SEC CIK
1595097
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
500 RIVER RIDGE DRIVE, NORWOOD, Massachusetts, 02062, United States
Fiscal year end
1231
Phone
617-963-0103

Similar stocks

Stock NameCountryMarket CapPE Ratio
Annexon, Inc. (ANNX)United States$0.147B-4.22
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88